Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin Open-Label Extension in Neuropsychiatric Symptoms
NCT03623321Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of pimavanserin in neurodegenerative disease, sponsored by Acadia Pharmaceuticals. Primary endpoint: Treatment-emergent Adverse Events at 56 weeks. Started Jul 2018; status: completed.
02
Drugs
pimavanserin
03
Conditions
neurodegenerative disease
Beyond the preview
Go deeper on NCT03623321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623321.